Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma - Wikidata - wikimedia - TriplyDB

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

http://www.wikidata.org/entity/Q28264437

about

Reduction of intraarticular adhesion of knee by local application of rapamycin in rabbits via inhibition of fibroblast proliferation and collagen synthesis.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Opening of the inward rectifier potassium channel alleviates maladaptive tissue repair following myocardial infarction.Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway.Critical effects of long non-coding RNA on fibrosis diseases.Sirtuins and Accelerated Aging in Scleroderma.Elevated TGF β2 serum levels in Emery-Dreifuss muscular dystrophy: implications for myocyte and tenocyte differentiation and fibrogenic processes.

P2860

Q36815605-8DE66FE6-766A-4603-9069-4B293E105F1D Q37649641-951ACFDB-D7D7-48C3-AC9E-B3B7236DB5D3 Q41914494-EDDC075F-EBAF-4843-8C90-71DEA249A372 Q47198646-8EC8B60A-A9B6-44DD-85E6-C7D9921C44C7 Q47848719-B2D85768-8ECA-4D2F-B260-7D8DC89CBE02 Q49922983-61628ECA-8A2A-4AD9-A43B-B549581C822D Q51762056-6ED6C6EE-B682-423C-8A67-2D354A8EE62E Q52564206-A6562BDE-C558-457E-B7DA-4DBDECEAC7E2

P2860

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

http://www.wikidata.org/entity/Q28264437

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@ast

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@en

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@nl

type

label

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@ast

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@en

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@nl

prefLabel

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@ast

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@en

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@nl

P1433

Q28264437-9F7BE4B7-706A-449C-942F-466A7E2244B5

P1476

Q28264437-C674F667-9E24-4F03-9B87-C22707D8A60F

P2093

Q28264437-03D2B14C-B4A3-4538-9830-52E7AED1DAA2

Q28264437-095A2D53-C963-4F43-A45F-6E64B1519F72

Q28264437-8D57391D-C57D-4783-8755-B7CB40878860

Q28264437-B670BDFE-3AC9-423C-8C69-E05DF52BF6C3

Q28264437-BA5E52F9-859B-47F6-A8C1-F125D8A2F344

Q28264437-C29CEC0E-97F4-442F-B98B-C123E3D34DF8

Q28264437-EFE2556C-9143-4841-97E0-764432C542E9

P2860

Q28264437-1798CA94-3919-450E-B7D7-6E786484C4A5

Q28264437-3D3BF21B-9264-43FF-8DEE-3D648A49F775

Q28264437-49A76514-B642-4A4D-8F77-A81F26D7C1A6

Q28264437-4A337D8D-993C-43EE-BDC8-70D7F2001C6C

Q28264437-51101FBD-889E-4CDE-B149-FCC599F3F0D6

Q28264437-58A28CC2-C8DE-4F2A-9DFD-9ABC453F0638

Q28264437-6977677D-78E5-4AD2-9652-CE76A12E2841

Q28264437-B8153BF4-F00D-41E6-8100-B895B39E5932

Q28264437-C78F8686-DC5F-42F5-AEE2-4F3EDDF558B4

Q28264437-CA433C9C-2046-4B3D-93A8-D55F7D9F0401

P2888

Q28264437-E119D6E9-B488-4742-B6C2-DCD736CB392B

P304

Q28264437-2F706BFD-AE28-4A4D-B47F-5A563D28302E

P31

Q28264437-2C994330-73CC-4945-9BF9-A3EE7B42FE13

P3181

Q28264437-62A98210-7C3E-43AF-8977-EBC859324930

P356

Q28264437-FDC37522-102C-4125-93A4-5290102A5BEA

P407

Q28264437-28DA0599-580D-457F-9B9D-D2252D65238A

P433

Q28264437-7537FC65-7AA9-4C9D-B566-950D03BF613A

P478

Q28264437-07C98BD0-141E-411A-8498-D79CD6E09660

P50

Q28264437-F712DBA0-06CB-4261-8A06-446E5844B6F5

P577

Q28264437-8E8FDCDF-833D-4C67-8C7E-D2B4008A9D1E

P5875

Q28264437-18EAFFF7-29C5-4B2E-8487-B4D6068996B0

P6179

Q28264437-AA9152F1-283A-41D0-B56D-ECD0F77ABE87

P698

Q28264437-AD3A07C1-FAF1-4784-8E9F-01533C193C33

P921

Q28264437-878D1E7E-4DDF-4A84-A999-36AC87264C2A

P932

Q28264437-1453E7CF-3300-46DF-ABE0-C3266585E197

P3181

P356

P1433

Journal of Investigative Dermatology

P1476

Dual mTOR Inhibition Is Requir ...... : Implications for Scleroderma

@en

P2093

Alexander Merleev

http://www.w3.org/2001/XMLSchema#string

Alina I Marusina

http://www.w3.org/2001/XMLSchema#string

Anupam Mitra

http://www.w3.org/2001/XMLSchema#string

David Fiorentino

http://www.w3.org/2001/XMLSchema#string

Jesus I Luna

http://www.w3.org/2001/XMLSchema#string

Siba P Raychaudhuri

http://www.w3.org/2001/XMLSchema#string

Smriti Kundu-Raychaudhuri

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma.

Efficacy of rapamycin in scleroderma: a case study.

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Multiscale biomimetic topography for the alignment of neonatal and embryonic stem cell-derived heart cells.

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target.

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

P2888

P304

2873-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2227400

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/JID.2015.252

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Emanual Maverakis

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279730197

http://www.w3.org/2001/XMLSchema#string

P6179

1040589370

http://www.w3.org/2001/XMLSchema#string

P698

26134944

http://www.w3.org/2001/XMLSchema#string

P921

P932

4640976

http://www.w3.org/2001/XMLSchema#string